JPS57209226A - Antitumor activity intensifier - Google Patents

Antitumor activity intensifier

Info

Publication number
JPS57209226A
JPS57209226A JP9467781A JP9467781A JPS57209226A JP S57209226 A JPS57209226 A JP S57209226A JP 9467781 A JP9467781 A JP 9467781A JP 9467781 A JP9467781 A JP 9467781A JP S57209226 A JPS57209226 A JP S57209226A
Authority
JP
Japan
Prior art keywords
intensifying
treated
intensifier
active radiation
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9467781A
Other languages
Japanese (ja)
Inventor
Juichi Nakatsugawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamasa Shoyu KK
Original Assignee
Yamasa Shoyu KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamasa Shoyu KK filed Critical Yamasa Shoyu KK
Priority to JP9467781A priority Critical patent/JPS57209226A/en
Publication of JPS57209226A publication Critical patent/JPS57209226A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

PURPOSE: A low-toxicity preparation that contains a specific guanosine derivative and/or an adenosine derivative as active ingredients, thus intensifying the antitumor effect, when a malignant tumor is treated with active radiation and/or an antitumor agent.
CONSTITUTION: The objective intensifier contains 6-thio-3'-deoxyguanosine and at least one selected from 2-amino-3'-deoxydenosine and its 5'-phosphoric esters. These compounds have an activity of intensifying the active radiation, when a cancer is treated with active radiation, so the dose can be reduced. Further, they also show a activity of intensifying the antitumor effect, when a malignant tumor is treated with a chemical. It is made into an oral preparation, injection solution or suppository and dosed in 0.5W3,000mg/day.
COPYRIGHT: (C)1982,JPO&Japio
JP9467781A 1981-06-18 1981-06-18 Antitumor activity intensifier Pending JPS57209226A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP9467781A JPS57209226A (en) 1981-06-18 1981-06-18 Antitumor activity intensifier

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9467781A JPS57209226A (en) 1981-06-18 1981-06-18 Antitumor activity intensifier

Publications (1)

Publication Number Publication Date
JPS57209226A true JPS57209226A (en) 1982-12-22

Family

ID=14116846

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9467781A Pending JPS57209226A (en) 1981-06-18 1981-06-18 Antitumor activity intensifier

Country Status (1)

Country Link
JP (1) JPS57209226A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025758A1 (en) * 1998-11-04 2000-05-11 Supergen, Inc. Oral administration of adenosine analogs
WO2014168947A3 (en) * 2013-04-08 2015-02-19 The Board Of Regents Of The University Of Texas System Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025758A1 (en) * 1998-11-04 2000-05-11 Supergen, Inc. Oral administration of adenosine analogs
WO2014168947A3 (en) * 2013-04-08 2015-02-19 The Board Of Regents Of The University Of Texas System Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere
AU2014251093B2 (en) * 2013-04-08 2017-06-15 The Board Of Regents Of The University Of Texas System Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere
US10463685B2 (en) 2013-04-08 2019-11-05 The Board Of Regents Of The University Of Texas System Telomerase mediated telomere altering compounds
RU2713555C2 (en) * 2013-04-08 2020-02-05 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Method for treatment of patients with large intestine cancer or lung cancer
EP3682888A1 (en) * 2013-04-08 2020-07-22 The Board of Regents of The University of Texas System Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere

Similar Documents

Publication Publication Date Title
JPS5735516A (en) Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
HUT37891A (en) Process for preparing synegretic mixtures of interferones and tumor necrosis factor
PH19881A (en) Tetracyclic t-butyl imidazo(1,5-a)(1,4)-diazepine-1-carboxylates,medicament containing same and method of use thereof
HU188768B (en) Fungicides, insecticides and acaricides,as well as process for the preparation of their amino-pyrimidine derivatives active ingredients
GB2116424B (en) Water soluable glass articles, their manufacture, and their use in the treatment of ruminant animals
FR08C0001I2 (en)
DE3160616D1 (en) Polyether compounds and their manufacture, resultant composition and the use of these products as medicaments or growth promoting agents in ruminants
JPS57209225A (en) Antitumor activity intensifier
EP0004680A3 (en) Pharmaceutical compositions, method of inhibiting and of treating cancerous tumours, and a nonatetraenoic acid
JPS57209226A (en) Antitumor activity intensifier
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
PT74654B (en) Process for the preparation of compositions in powder form containing pesticides and suitable for treatment of house hold furnishing
EP0073251A4 (en) Agent for treating diseases of respiratory organs.
CA2206566A1 (en) Method and composition for reducing tumor development with a combination of platinum and tellurium or selenium compounds
ES2019713A6 (en) Treatment of malignant tumors with 8-chloroadenosine 3',5'-cyclic phosphate, 8-aminoadenosine 3',5'-cyclic phosphate and preparation thereof.
JPS56120700A (en) Cardiac stimmulant
Kim et al. Human Herpesvirus-8 Positive Multicentric Castleman’s Disease with Complete Response after Rituximab Monotherapy: A Case Report
JPS5524150A (en) Anti-malignant-tumor agent
JPS5562093A (en) Immunoregulating agent containing thiazolo 3,2-a pyrimidine derivative
Fujita Monitoring for internal contamination
Abe et al. A randomized controlled study of (2''R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer
Madoc-Jones et al. New cesium tables for rapid calculation of intracavitary dose to the vagina
Dedov et al. Comparative biological efficacy of super (125) I and super (131) I.
JPS5690015A (en) Preventive and remedy containing human ceruloplasmin as main component
DE3161905D1 (en) 5-sulfamoyl-orthanilic acids, processes for their preparation, therapeutic compositions containing them and the compounds for use in therapy